BFRI:NSD-Biofrontera Inc. Common Stock (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 2.88

Change

0.00 (0.00)%

Market Cap

USD 0.05B

Volume

0.27M

Avg Analyst Target

USD 15.50 (+438.19%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Biofrontera Inc. Common Stock (BFRI) Stock Analysis:
Based on the Biofrontera Inc. Common Stock stock forecasts from 2 analysts, the average analyst target price for Biofrontera Inc. Common Stock is USD 15.50 over the next 12 months. Biofrontera Inc. Common Stock’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Biofrontera Inc. Common Stock is Very Bearish, which is based on 0 positive signals and 3 negative signals. At the last closing, Biofrontera Inc. Common Stock’s stock price was USD 2.88. Biofrontera Inc. Common Stock’s stock price has changed by +3.97% over the past week, -24.21% over the past month and 0% over the last year.

About

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-21 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
NBIX Neurocrine Biosciences Inc

N/A

USD8.24B 118.05 61.37
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
ITCI Intra-Cellular Therapies Inc

N/A

USD5.45B N/A N/A
PCRX Pacira BioSciences Inc

N/A

USD2.86B 75.14 26.41
TLRY Tilray Inc

N/A

USD2.42B 50.63 N/A
CGC Canopy Growth Corporation

N/A

USD2.32B N/A N/A
IRWD Ironwood Pharmaceuticals Inc

N/A

USD1.76B 3.72 6.96
HCM HUTCHMED (China) Limited

N/A

USD1.66B 17.69 N/A

ETFs Containing BFRI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -61.70% 30% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -61.70% 30% F 15% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.05B 34% F 17% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.56 43% F 33% F
Price / Cash Flow Ratio -1.79 56% F 61% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -290.39% 9% F 4% F
Return on Invested Capital -294.27% 3% F 5% F
Return on Assets -26.72% 27% F 15% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.25 90% A- 90% A-
Short Percent 11.15% 25% F 16% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.